In The News Posted December 21, 2020 Share Posted December 21, 2020 SAN RAFAEL, Calif., Dec. 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP),...View the full article Quote Link to comment Share on other sites More sharing options...
Recommended Posts